Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.60
Bid: 1,704.60
Ask: 1,705.60
Change: 0.40 (0.02%)
Spread: 1.00 (0.059%)
Open: 1,701.60
High: 1,708.60
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

STOCKS NEWS EUROPE-Shire weakens on trial failures

Fri, 07th Feb 2014 09:29

Shares in Shire fall 1.1 percent in brisk trade after Vyvanse, atop-selling medicine for hyperactivity, fails in two late-stage clinical trialsto successfully treat adults with major depressive disorders.

Some traders see scope for a further near-term sell-off in Shire, up around9 percent in 2014 against a drop of about 3 percent on broader the FTSE 100, with the recent gains having been driven partly by speculation of atakeover attempt on the pharmaceuticals group.

"I think it should go down more; it's obviously a blow to the company... Ithink you'll see a quite negative pull-back to 28 quid ($45.71)," says JoeRundle, head of trading at ETX Capital.

"If there's a big sell-off in the stock (to 28 pounds) bid speculation willcome back... into play in a more serious manner," he says. Such a drop wouldtake the shares some 10 percent below the current 3,107.98 pence level.

Others are more sanguine on the company, highlighting its longer-term growthpotential.

"Significant news flow could still boost belief in Shire's longer-termorganic growth prospects, which together with EPS growth acceleratingpotentially (by more than) 15 percent can justify multiple expansion," sayanalysts at Jefferies in a note. They rate the shares as a "buy".

Jefferies' stance echoes that of the broader market, where the averagerecommendation on Shire going into today's news was a "buy", according toThomson Reuters Starmine data.

And, based on Starmine's Analysts Revision Model (ARM) - which measuresanalysts' revisions of key indicators such as earnings and revenue estimates andchanges to their ratings - Shire is ranked way above London-listed peersAstraZeneca and GlaxoSmithKline.

"I think the push lower this morning will likely have been an intra-dayoverreaction and technically the uptrend remains intact and it becomes anopportunity to position yourself 'long' ahead of figures (full-year results) onthe 13th of February," Jordan Hiscott, senior trader at Gekko Global Markets,says.

Trading volumes in Shire stand at a chunky 90 percent of the 90-day dailyaverage, against just 14 percent on the UK benchmark.

For more on Vyvanse trial failures:

Reuters messaging rm://tricia.wright1.thomsonreuters.com@reuters.net

($1 = 0.6125 British pounds)

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.